MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Condition(s) studied

Investigational drug(s) / intervention(s)

Allogeneic Hematopoietic Stem Cell Transplantation: Given IV

Azacitidine: Given IV or SC

Best Practice: Receive SOC treatment

Biopsy Procedure: Undergo biopsy

Biospecimen Collection: Undergo collection of blood, urine, and/or buccal swab samples

Bone Marrow Aspiration: Undergo bone marrow aspiration

Bone Marrow Biopsy: Undergo bone marrow biopsy

Busulfan: Given IV

Chest Radiography: Undergo chest x-ray

Computed Tomography: Undergo CT

Cytarabine: Given

Daunorubicin Hydrochloride: Given IV

Decitabine and Cedazuridine: Given PO

Echocardiography Test: Undergo ECHO

Emavusertib: Given PO

Enasidenib: Given PO

Epoetin Alfa: Given SC

Fludarabine: Given IV

Gemtuzumab Ozogamicin: Given IV

Gilteritinib: Given PO

Liposome-encapsulated Daunorubicin-Cytarabine: Given IV

Luspatercept: Given SC

Melphalan: Given IV

Multigated Acquisition Scan: Undergo MUGA

Mutation Carrier Screening: Undergo rapid genetic testing

Olutasidenib: Given PO

Placebo Administration: Given PO

Positron Emission Tomography: Undergo PET

Total-Body Irradiation: Undergo total body irradiation

Venetoclax: Given PO

Study summary

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Eligibility

Primary outcome measure(s)

• Timing of treatment Substudy or Tier Advancement Pathway (TAP) assignment — Within 72 hours of MDNet receipt of specimens for initial therapy or within 10 days for subsequent therapy
  Will evaluate the feasibility of MATCHBox generating all data needed for assignment to a myeloMATCH clinical trial or determination that no assignment is available, within 72 hours of MDNet receipt of specimens for initial therapy and within 10 days for subsequent therapy. For first treatment assignment and separately for each subsequent treatment assignments: every 50 participants for the first 250 participants and then every 100 participants thereafter, the proportion of participants (cumulative and new participants since prior analysis) with all MDNet data needed to determine a treatment assignment within 72 hours for first assignment and 10 days for subsequent assignments after the MDNet receives specimens will be tallied.

Trial sites (350)

+ 310 more sites — see the full list on the official registry below.

On this site

More National Cancer Institute (NCI) trials in Canada

Other trials for the same condition